Media Relations News Releases Year: - Any -2019201820172016 Items per page 102550 Jun 1, 2019 Summary ToggleNovartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial May 24, 2019 Summary ToggleFDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer May 8, 2019 Summary ToggleNovartis data at AAN show Mayzent’s® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS May 2, 2019 Summary ToggleNovartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN Mar 26, 2019 Summary ToggleNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease Jan 29, 2019 Summary ToggleNovartis delivered accretive growth, focused the company and built leading advanced therapy platforms in 2018 Dec 13, 2018 Summary ToggleNovartis receives European Commission approval for self-administration of Xolair® across all indications Nov 27, 2018 Summary ToggleNovartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe Nov 23, 2018 Summary ToggleNovartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease Nov 16, 2018 Summary ToggleNovartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
